Literature DB >> 31451515

Long-term progression in type II spinal muscular atrophy: A retrospective observational study.

Eugenio Mercuri1, Simona Lucibello2, Maria Carmela Pera2, Sara Carnicella2, Giorgia Coratti2, Roberto de Sanctis2, Sonia Messina2, Elena Mazzone2, Nicola Forcina2, Lavinia Fanelli2, Giulia Norcia2, Laura Antonaci2, Anna Lia Frongia2, Marika Pane2.   

Abstract

OBJECTIVE: To report the long-term progression in a cohort of patients with type II spinal muscular atrophy (SMA) assessed with the Hammersmith Functional Motor Scale-Expanded.
METHODS: Seventy-three patients (age 2.6-25 years) were included in the study. Twenty-eight of the 73 were first assessed before the age of 5 years and had been followed up for ≈5 years or longer. We observed an overall progression that was not linear. A piecewise regression analysis showed an improvement of scores in the younger patients with a point of slope change at ≈5 years of age, a decline between 5 and 13 years of age, and stability/slower decline after that.
RESULTS: Patients with the lowest scores at baseline had the earliest onset of scoliosis and a higher need for noninvasive ventilation compared to those with higher scores. Our results confirm that on the long-term follow-up all patients with type II SMA show a clear and progressive decline.
CONCLUSION: The severity of functional impairment at baseline can help to predict the magnitude of changes over time and the overall progression, including onset of scoliosis and need for noninvasive ventilation.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31451515     DOI: 10.1212/WNL.0000000000008166

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

2.  Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study.

Authors:  Giorgia Querin; Timothée Lenglet; Rabab Debs; Tanya Stojkovic; Anthony Behin; François Salachas; Nadine Le Forestier; Maria Del Mar Amador; Gaëlle Bruneteau; Pascal Laforêt; Sophie Blancho; Véronique Marchand-Pauvert; Peter Bede; Jean-Yves Hogrel; Pierre-François Pradat
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

Review 3.  Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.

Authors:  Claudia A Chiriboga
Journal:  Paediatr Drugs       Date:  2022-08-27       Impact factor: 3.930

4.  Different trajectories in upper limb and gross motor function in spinal muscular atrophy.

Authors:  Giorgia Coratti; Maria Carmela Pera; Jacqueline Montes; Amy Pasternak; Mariacristina Scoto; Giovanni Baranello; Sonia Messina; Sally Dunaway Young; Allan M Glanzman; Tina Duong; Roberto De Sanctis; Elena Stacy Mazzone; Evelin Milev; Annemarie Rohwer; Matthew Civitello; Marika Pane; Laura Antonaci; Anna Lia Frongia; Maria Sframeli; Gian Luca Vita; Adele DʼAmico; Irene Mizzoni; Emilio Albamonte; Basil T Darras; Enrico Bertini; Valeria A Sansone; Francesca Bovis; John Day; Claudio Bruno; Francesco Muntoni; Darryl C De Vivo; Richard Finkel; Eugenio Mercuri
Journal:  Muscle Nerve       Date:  2021-08-09       Impact factor: 3.852

5.  Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.

Authors:  Federica Trucco; Deborah Ridout; Mariacristina Scoto; Giorgia Coratti; Marion L Main; Robert Muni Lofra; Anna G Mayhew; Jacqueline Montes; Marika Pane; Valeria Sansone; Emilio Albamonte; Adele D'Amico; Enrico Bertini; Sonia Messina; Claudio Bruno; Deepak Parasuraman; Anne-Marie Childs; Vasantha Gowda; Tracey Willis; Min Ong; Chiara Marini-Bettolo; Darryl C De Vivo; Basil T Darras; John Day; Elizabeth A Kichula; Oscar H Mayer; Aledie A Navas Nazario; Richard S Finkel; Eugenio Mercuri; Francesco Muntoni
Journal:  Neurology       Date:  2020-10-16       Impact factor: 9.910

6.  Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy.

Authors:  Marika Pane; Giorgia Coratti; Maria Carmela Pera; Valeria A Sansone; Sonia Messina; Adele d'Amico; Claudio Bruno; Francesca Salmin; Emilio Albamonte; Roberto De Sanctis; Maria Sframeli; Vincenzo Di Bella; Simone Morando; Concetta Palermo; Anna Lia Frongia; Laura Antonaci; Anna Capasso; Michela Catteruccia; Antonella Longo; Martina Ricci; Costanza Cutrona; Alice Pirola; Chiara Bravetti; Marina Pedemonte; Noemi Brolatti; Enrico Bertini; Eugenio Mercuri
Journal:  Ann Clin Transl Neurol       Date:  2022-02-15       Impact factor: 4.511

7.  Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study.

Authors:  Giorgia Coratti; Jacopo Lenkowicz; Stefano Patarnello; Consolato Gullì; Maria Carmela Pera; Carlotta Masciocchi; Riccardo Rinaldi; Valeria Lovato; Antonio Leone; Alfredo Cesario; Eugenio Mercuri
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.240

8.  Body mass index in type 2 spinal muscular atrophy: a longitudinal study.

Authors:  Gloria Ferrantini; Giorgia Coratti; Roberta Onesimo; Simona Lucibello; Sarah Bompard; Ida Turrini; Graziamaria Cicala; Michela Caprarelli; Maria Carmela Pera; Chiara Bravetti; Beatrice Berti; Valentina Giorgio; Claudio Bruno; Noemi Brolatti; Chiara Panicucci; Adele D'Amico; Antonella Longo; Chiara Leoni; Valeria A Sansone; Emilio Albamonte; Sonia Messina; Maria Sframeli; Enrico Bertini; Marika Pane; Eugenio Mercuri
Journal:  Eur J Pediatr       Date:  2022-01-19       Impact factor: 3.860

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.